UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars - UnitedHealth Group ( NYSE:UNH )
UnitedHealth Group Inc. UNH reportedly announced on Tuesday that it will remove AbbVie Inc.'s ABBV blockbuster drug Humira from some of its preferred reimbursement lists starting January 1, 2025. The company will recommend lower-cost biosimilar versions instead.
| Ticker |
Sentiment |
Impact |
|
CVS
|
Neutral
|
18 %
|
|
ABBV
|
Somewhat Bullish
|
34 %
|
|
TEVA
|
Neutral
|
18 %
|
|
AMGN
|
Neutral
|
18 %
|
|
PFE
|
Neutral
|
18 %
|
|
UNH
|
Somewhat Bullish
|
34 %
|
